Synthesis and structure-activity relationships of β- and α-piperidine sulfone hydroxamic acid matrix metalloproteinase inhibitors with oral antitumor efficacy

Journal of Medicinal Chemistry

Volumn 48, Issue 21, 2005, Pages 6713-6730

  Becker, Daniel P ^a   Villamil, Clara I ^b   Barta, Thomas E ^c   Bedell, Louis J ^d   Boehm, Terri L ^f   DeCrescenzo, Gary A ^f   Freskos, John N ^f   Getman, Daniel P ^f   Hockerman, Susan ^f   Heintz, Robert ^f   Howard, Susan Carol ^e   Li, Madeleine H ^f   McDonald, Joseph J ^f   Carron, Chris P ^f   Funckes Shippy, Chris L ^f   Mehta, Pramod P ^f   Munie, Grace E ^f   Swearingen, Craig A ^f  

^a LOYOLA UNIVERSITY CHICAGO   (United States)

^b ABBOTT LABORATORIES   (United States)

^c Serenex Inc   (United States)

^d DeCODE Chemistry & Biostructures   (United States)

^e MALLINCKRODT PHARMACEUTICALS   (United States)

^f NONE

Author keywords

[No Author keywords available]

Indexed keywords

4 [[[4 (4 CHLOROPHENOXY)PHENYL]SULFONYL]METHYL]TETRAHYDRO 2H PYRAN 4 CARBOHYDROXAMIC ACID; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; COLLAGENASE 3; GELATINASE A; GELATINASE B; HYDROXAMIC ACID DERIVATIVE; INTERSTITIAL COLLAGENASE; MARIMASTAT; MATRIX METALLOPROTEINASE INHIBITOR; N HYDROXY 4 [[4 (PHENYLTHIO)PHENYL]SULFONYL] 1 (2 PROPYNYL) 4 PIPERIDINECARBOXAMIDE; NEUTROPHIL COLLAGENASE; PACLITAXEL; PIPERIDINE DERIVATIVE; PRINOMASTAT; REBIMASTAT; SC 276; SULFONE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CARCINOMA; CANCER INHIBITION; CHIRALITY; CONTROLLED STUDY; CORNEA NEOVASCULARIZATION; DRUG POTENCY; DRUG SELECTIVITY; DRUG SYNTHESIS; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; MALE; MOUSE; NONHUMAN; STRUCTURE ACTIVITY RELATION; SURVIVAL TIME; TUMOR XENOGRAFT;

ADMINISTRATION, ORAL; ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; HYDROXAMIC ACIDS; MAMMARY NEOPLASMS, EXPERIMENTAL; MATRIX METALLOPROTEINASES; MICE; MICE, NUDE; PACLITAXEL; PIPERIDINES; STRUCTURE-ACTIVITY RELATIONSHIP; SULFONES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 27144532804     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm0500875     Document Type: Article

References (42)

1. Brinckerhoff, C. E.; Matrisian, L. M. Matrix metalloproteinases: A tail of a frog that became a prince. Nat. Rev. Mol. Cell Biol. 2002, 3, 207-214.
2. Doherty, T. M.; Asotra, K.; Pei, D.; Uzui, H.; Wilkin, D. J.; Shah, P. K.; Rajavashisth, T. B. Therapeutic developments in matrix metalloproteinase inhibition. Expert Opin. Ther. Pat. 2002, 12, 665-707.
3. Nagase, H.; Woessner, J. F., Jr. Matrix metalloproteinases. J. Biol. Chem. 1999, 274, 21491-21494.
4. Wojtowicz-Praga, S. M.; Dickson, R. B.; Hawkins, M. J. Matrix metalloproteinase inhibitors. Invest. New Drugs 1997, 15, 61-75.
5. Skiles, J. W.; Gonnella, N. C.; Jeng, A. Y. The design, structure and therapeutic application of matrix metalloproteinase inhibitors. Curr. Med. Chem. 2001, 8, 425-474.
6. Woessner, J. F., Jr. Matrix metalloproteinases and their inhibitors in connective tissue remodeling. FASEB J. 1991, 5, 2145-2154.
7. Martel-Pelletier, J.; Welsch, D. J.; Pelletier, J. P. Metalloproteases and inhibitors in arthritic diseases. Best Pract. Res. Clin. Rheumatol. 2001, 15, 805-829.
8. Heath, E. I.; Grochow, L. B. Clinical potential of matrix metalloprotease inhibitors in cancer therapy. Drugs 2000, 59, 1043-1055.
9. Hidalgo, M.; Eckhardt, G. Development of matrix metalloproteinase inhibitors in cancer therapy. J. Natl. Cancer Inst. 2001, 93, 178-193.
10. Fingleton, B. Matrix metalloproteinase inhibitors for cancer therapy: The current situation and future prospects. Expert Opin. Ther. Targets 2003, 7, 385-397.
11. Matter, A. Tumor angiogenesis as a therapeutic target. Drug Discovery Today 2001, 6, 1005-1024.
12. Supuran, C. T.; Casini, A.; Scozzafava, A. Protease inhibitors of the sulfonamide type: Anticancer, antiinflammatory and antiviral agents. Med. Res. Rev. 2003, 23, 535-558.
13. Casini, A.; Scozzafava, A.; Supuran, C. T. Sulfonamide derivatives with protease inhibitory action as anticancer, antiinflammatory and antiviral agents. Expert Opin. Ther. Pat. 2002, 12, 1307-1327.
14. Supuran, C. T.; Scozzafava, A. Matrix metalloproteinases (MMPs). In Proteinase and Peptidase Inhibition: Recent Potential Tartets for Drug Development; Smith, H. J., Simons, C., Eds.; Taylor & Francis: London and New York, 2002; pp 35-61.
15. Stamenkovic, I. Matrix metalloproteinases in tumor invasion and metastasis. Semin. Cancer Biol. 2000, 10, 415-433.
16. Yip, D.; Ahmad, A.; Karapetis, C. S.; Hawkins, C. A.; Harper, P. G. Matrix metalloproteinase inhibitors: Applications in oncology. Invest. New Drugs 1999, 17, 387-399.
17. Nelson, A. R.; Fingleton, B.; Rothenberg, M. L.; Matrisian, L. M. Matrix metalloproteinases: Biologic activity and clinical implications. J. Clin. Oncol. 2000, 18, 1135-1149.
18. Coussens, L. M.; Fingleton, B.; Matrisian, L. M. Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science 2002, 295, 2387-2392.
19. Hidalgo, M.; Eckhardt, S. G. Development of matrix metalloproteinase inhibitors in cancer therapy. J. Natl. Cancer Inst. 2001, 93, 178-193.
20. Bramhall, S. R.; Hallissey, M. T.; Whiting, J.; Scholefield, J.; Tierney, G.; Stuart, R. C.; Hawkins, R. E.; McCulloch, P.; Maughan, T.; Brown, P. D.; Baillet, M.; Fielding, J. W. L. Marimastat as maintenance therapy for patients with advanced gastric cancer: A randomized trial. Br. J. Cancer 2002, 86, 1864-1870.
21. Groves, M. D.; Puduvalli, V. K.; Hess, K. R.; Jaeckle, K. A.; Peterson, P.; Yung, W. K. A.; Levin, V. A. Phase II trial of temozolomide plus the matrix metalloproteinase inhibitor, marimastat, in recurrent and progressive glioblastoma multiforme. J. Clin. Oncol. 2002, 20, 1383-1388.
22. Bramhall, S. R.; Rosemurgy, A.; Brown, P. D.; Bowry, C.; Buckels, J. A. Marimastat as first-line therapy for patients with unresectable pancreatic cancer: A randomized trial. J. Clin. Oncol. 2001, 19, 3447-3455.
23. Naglich, J. G.; Jure-Kunkel, M.; Gupta, E.; Fargnoli, J.; Henderson, A. J.; Lewin, A. C.; Talbott, R.; Baxter, A.; Bird, J.; Savopoulos, R.; Wills, R.; Kramer, R. A.; Trail, P. A. Inhibition of angiogenesis and metastasis in two murine models by the matrix metalloproteinase inhibitor, BMS-275291. Cancer Res. 2001, 61, 8480-8485.
24. Renkiewicz, R.; Qiu, L.; Lesch, C.; Sun, X.; Devalaraja, R.; Cody, T.; Kaldjian, E.; Welgus, H.; Baragi, V. Broad-spectrum matrix metalloproteinase inhibitor marimastat induced musculoskeletal side effects in rats. Arthritis Rheum. 2003, 48, 1742-1749.
25. Brown, P. D. Clinical studies with matrix metalloproteinase inhibitors. APMIS 1999, 107, 174-180.
26. Becker, D. P.; Barta, T. E.; Bedell, L.; DeCrescenzo, G.; Freskos, J.; Getman, D. P.; Hockerman, S. L.; Li, M.; Mehta, P.; Mischke, B.; Munie, G. E.; Swearingen, C.; Villamil, C. I. α-Amino-β-sulphone hydroxamates as potent MMP-13 inhibitors that spare MMP-1. Bioorg. Med. Chem. Lett. 2001, 11, 2719-2722.
27. Becker, D. P.; DeCrescenzo, G.; Freskos, J.; Getman, D. P.; Hockerman, S. L.; Li, M.; Mehta, P.; Munie, G. E.; Swearingen, C. α-Alkyl-α- amino-β-sulphone hydroxamates as potent MMP inhibitors that spare MMP-1. Bioorg. Med. Chem. Lett. 2001, 11, 2723-2725.
28. Lollini, L.; Haller, J.; Eugui, E. M.; Womble, S. W.; Martin, R.; Campbell, J. Disease modification by RS-130830, a collagenase-3 selective inhibitor, in experimental osteoarthritis (OA) [abstract]. Arthritis Rheum. 1997, 40 (Suppl.), S87, abstract 341.
29. Close, D. R. Matrix metalloproteinase inhibitors in rheumatic diseases. Ann. Rheum. Dis. 2001, 60, iii62-iii67.
30. Becker, D.; Barta, T.; Bedell, L.; Boehm, T.; Carron, C.; DeCrescenzo, G.; Freskos, J.; Funckes-Shippy, C.; Getman, D.; Hockerman, S.; Li, M.; McDonald, J.; Mehta, P.; Munie, G.; Rico, J.; Shieh, H.; Stevens A.; Swearingen, C. Design and synthesis of potent and orally active MMP-1 sparing matrix metalloproteinase inhibitors with efficacy in antitumor models. Oral Presentation at the 222nd ACS National Meeting, Chicago, IL, August 26-30, 2001. Abstr. Pap. Am. Chem. Soc., Medi 018, 2001.
31. Barta, T. E.; Becker, D. P.; Boehm, T. L.; DeCrescenzo, G. A.; Villamil, C. I.; McDonald, J. J.; Freskos, J. N.; Getman, D. P. Preparation of arylsulfonyl heterocyclyl hydroxamic acids and related compounds as matrix metalloprotease inhibitors. U.S. Patent 6,541,489, 2003. PCT Int. Appl. WO 9925687 A1 990527 CAN 131:18929; AN 1999:350651.
32. Aranapakam, V.; Grosu, G. T.; Davis, J. M.; Hu, B.; Ellingboe, J.; Baker, J. L.; Skotnicki, J. S.; Zask, A.; DiJoseph, J. F.; Sung, A.; Sharr, M. A.; Killar, L. M.; Walter, T.; Jin, G.; Cowling, R. Synthesis and structure-activity relationship of α-sulfonyl-hydroxamic acids as novel, orally active matrix metalloproteinase inhibitors for the treatment of osteoarthritis. J. Med. Chem. 2003, 46, 2361-2375.
33. Aranapakam, V.; Davis, J. M.; Grosu, G. T.; Baker, J.; Ellingboe, J.; Zask, A.; Levin, J. I.; Sandanayaka, V. P.; Du, J.; Skotnicki, J. S.; DiJoseph, J. F.; Sung, A.; Sharr, M. A.; Killar, L. M.; Walter, T.; Jin, G.; Cowling, R.; Tillett, J.; Zhao, W.; McDevitt, J.; Xu, Z. B. Synthesis and structure-activity relationship of N-substituted 4-arylsulfonylpiperidine-4-hydroxamic acids as novel, orally active matrix metalloproteinase inhibitors for the treatment of osteoarthritis. J. Med. Chem. 2003, 46, 2376-2396.
34. Cignarella, G.; Villa, S.; Barlocco, D. Synthesis and pharmacological evaluation of a new class of 2-oxo-8-azaspiro (4,5)decan-1-ones as analogues of the muscarinic agonist RS-86. Farmaco 1993, 48, 1439-1445.
35. Veber, D. F.; Johnson, S. R.; Cheng, H.-Y.; Smith, B. R.; Ward, K. W.; Kopple, K. D. Molecular properties that influence the oral bioavailability of drug candidates. J. Med. Chem. 2002, 45, 2615-2623.
36. Folkman, J.; Ingber, D. Inhibition of angiogenesis. Semin. Cancer Biol. 1992, 3, 89-96.
37. Blood, C. H.; Zetter, B. R. Tumor interactions with the vasculature: Angiogenesis and tumor metastasis. Biochim. Biophys. Acta 1990, 1032, 89-118.
38. D'Amore, P. A. Capillary growth: A two-cell system. Semin. Cancer Biol. 1992, 3, 49-56.
39. Sunderkotter, C.; Steinbrink, K.; Goebeler, M.; Bhardwaj, R.; Sorg, C. Macrophages and angiogenesis. J. Leukocyte Biol. 1994, 55, 410-422.
40. Gillaspy, M. L.; Lefker, B. A.; Hada, W. A.; Hoover, D. J. Tetracyclopropylmethane: A unique hydrocarbon with S4 symmetry. Tetrahedron Lett. 1995, 36, 7399-7402.
41. Nagase, H.; Fields, C. G.; Fields, G. B. Design and characterization of a fluorogenic substrate selectively hydrolyzed by stromelysin 1 (matrix metalloproteinase-3). J. Biol. Chem. 1994, 269, 20952-20957.
42. Knight, C. G.; Willenbrock, F.; Murphy, G. A novel coumarin-labeled peptide for sensitive continuous assay of matrix metalloproteinases. FEBS Lett. 1992, 296, 263-266.